NCT03911388
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
At risk: Primary completion moved at least 1 year 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 31 versions: 19 with changes below, 12 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Dec 31, 2027 Show 5 more changesShow less
- Eligibility criteria expanded, about 28 words
- Secondary endpoints: details revised at 1 of 6 entries
- Study description revised
- Site contacts updated at 1 of 3 sites
- Collaborators: details revised at 1 of 2 entries
- Minor Site contacts updated at 1 of 3 sitesv30
- Minor Site details revised at 2 of 3 sitesv29
- Notable Eligibility criteria expanded, about 143 words
- Secondary endpoints revised (6)
- Study sites revised (3)
- Notable Trial status: Active, Not Recruiting to Recruiting
- Site details revised at 3 of 3 sites
Show 13 earlier versionsHide 13 earlier versions
- Notable Lead sponsor: Gregory K. Friedman, MD to M.D. Anderson Cancer Centerv22
- Notable Primary completion date: Sep 1, 2025 to Sep 1, 2026
- Study completion date: Sep 1, 2026 to Sep 1, 2027
- Notable Enrollment target: 15 to 24
- Trial status: Recruiting to Active, Not Recruiting
- Study sites: 1 to 3
- Study description expanded, about 12 words
- Notable Primary completion date: Sep 1, 2024 to Sep 1, 2025
- Study completion date: Sep 1, 2025 to Sep 1, 2026
- Minor Collaborators: 3 to 2v18
- Notable Eligibility criteria expanded, about 39 wordsv17
- Notable Lead sponsor: University of Alabama at Birmingham to Gregory K. Friedman, MDv16
- Minor Collaborators expanded, about 11 wordsv15
- Notable Primary completion date: Sep 1, 2023 to Sep 1, 2024
- Study completion date: Sep 1, 2024 to Sep 1, 2025
- Site contact updated
- Notable Primary completion date: Sep 1, 2022 to Sep 1, 2023
- Eligibility criteria shortened, about 17 words
- Study completion date: Sep 1, 2023 to Sep 1, 2024
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 1, 2019 to Sep 12, 2019
- Site details revised
- Notable Start date: Jul 1, 2019 to Sep 1, 2019
- Primary completion date: Jul 1, 2022 to Sep 1, 2022
- Study completion date: Jul 1, 2023 to Sep 1, 2023
- Minor Secondary endpoints: details revised at 1 of 6 entries
- Study title shortened, about 5 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Safety and Tolerability as Measured by Frequency of Grade 3 or Above Adverse Events
Timeframe: Baseline to 15 years
Secondary (6)
Immunologic Response
Virologic Shedding
Progression Free Survival
Overall Survival
Change in Performance Score (Ability to Perform Normal Activities)
Show 1 moreShow less
Quality of Life (optional)
Arms and interventions
HSV G207Experimental
Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.
Biologicals: G207
Sites
3 sites in 1 country